Help
RSS
API
Feed
Maltego
Contact
Domain > www.cocrystalpharma.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2021-09-13
3.221.176.71
(
ClassC
)
2022-02-19
3.225.74.242
(
ClassC
)
2023-06-05
54.204.13.102
(
ClassC
)
2023-10-01
54.145.232.231
(
ClassC
)
2026-01-04
52.53.61.56
(
ClassC
)
Port 443
HTTP/1.1 200 OKDate: Sun, 04 Jan 2026 11:40:08 GMTServer: ApacheVary: Accept-EncodingTransfer-Encoding: chunkedContent-Type: text/html; charsetUTF-8 !DOCTYPE html>!--if lt IE 7> html classno-js lt-ie9 lt-ie8 lt-ie7 langen> !endif-->!--if IE 7> html classno-js lt-ie9 lt-ie8 langen> !endif-->!--if IE 8> html classno-js lt-ie9 langen> !endif-->!--if gt IE 8>!--> html classno-js langen> !--!endif--> head> meta charsetutf-8> title>Cocrystal Pharma, Inc. (COCP)/title> meta propertyog:title contentCocrystal Pharma, Inc.> meta propertyog:image contenthttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/social-image.jpg> meta nametwitter:card contentsummary_large_image> meta nameviewport contentinitial-scale1.0, widthdevice-width> link href//fonts.googleapis.com/css?familyOpen+Sans:400italic,400,300,600,700 relstylesheet typetext/css> link relstylesheet hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/css/fonts.css> link relstylesheet hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/css/bootstrap.min.css> link relstylesheet hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/css/bootstrap-select.min.css> link relstylesheet hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/css/fancybox.css> link relstylesheet hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/css/style.css> link relapple-touch-icon sizes57x57 hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/apple-touch-icon-57x57.png> link relapple-touch-icon sizes60x60 hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/apple-touch-icon-60x60.png> link relapple-touch-icon sizes72x72 hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/apple-touch-icon-72x72.png> link relapple-touch-icon sizes76x76 hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/apple-touch-icon-76x76.png> link relapple-touch-icon sizes114x114 hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/apple-touch-icon-114x114.png> link relapple-touch-icon sizes120x120 hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/apple-touch-icon-120x120.png> link relapple-touch-icon sizes144x144 hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/apple-touch-icon-144x144.png> link relapple-touch-icon sizes152x152 hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/apple-touch-icon-152x152.png> link relapple-touch-icon sizes180x180 hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/apple-touch-icon-180x180.png> link relicon typeimage/png hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/favicon-32x32.png sizes32x32> link relicon typeimage/png hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/android-chrome-192x192.png sizes192x192> link relicon typeimage/png hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/favicon-96x96.png sizes96x96> link relicon typeimage/png hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/favicon-16x16.png sizes16x16> link relmanifest hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/manifest.json> meta namemsapplication-TileColor content#ff0000> meta namemsapplication-TileImage contenthttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/mstile-144x144.png> meta nametheme-color content#ffffff> !--if lt IE 9>link relstylesheet hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/css/ie-8.css>!endif--> !--if IE 9>style>.main-nav ul li{white-space: normal;}/style>!endif--> script srchttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/js/aside/_js/modernizr.custom.min.js>/script> script> (function(i,s,o,g,r,a,m){iGoogleAnalyticsObjectr;irir||function(){ (ir.qir.q||).push(arguments)},ir.l1*new Date();as.createElement(o), ms.getElementsByTagName(o)0;a.async1;a.srcg;m.parentNode.insertBefore(a,m) })(window,document,script,https://www.google-analytics.com/analytics.js,ga); ga(create, UA-62215208-1, cocrystalpharma.com); (function() { var opts {}; var prefix /investor-relations; if (location.hostname.indexOf(dev-ir.stockpr.com) 0) { opts.cookiePath location.pathname.substring(0, location.pathname.indexOf(/, 1) + 1) opts.page prefix + location.pathname.substring(location.pathname.indexOf(/, 1)); } else if (location.hostname.match(/^ir\./)) { opts.page prefix + location.pathname; } ga(send, pageview, opts); })(); /** * Function that tracks a click on an outbound link in Analytics. * This function takes a valid URL string as an argument, and uses that URL string * as the event label. Setting the transport method to beacon lets the hit be sent * using navigator.sendBeacon in browser that support it. */ var trackOutboundLink function(url,category) { if (!category) category outbound; ga(send, event, category, click, url, { transport: beacon }); } window.onload function() { // Add outbound link tracking in GA $(a).not(.fancybox).each(function(){ var href $(this).attr(href); if (typeof href undefined) return; if (href.indexOf(http) > 0 && ( href.indexOf(website_base_url) 0 && href.indexOf(ir_base_url) 0 && href.indexOf(/cocrystalpharma) 0)) { $(this).attr(onclick, trackOutboundLink( + href + )); } else { // Its not an outbound link, but if its a link to a file, we want to track that. if (href.match(/(\.pdf|\.jpg|\.png|\.gif|\.ppt|\.jpeg|\.mp3|\.mp4|\.wav|\.docx|\.doc|\.xsl|\.cslx)/g)) { $(this).attr(onclick, trackOutboundLink( + href + , documents-and-files)); } } }); }; /script> /head> body classhome> div classgeneral-wrapper> header> div classzero-nav> div classcontainer> ul classsocial-media> li>a target_blank class hrefhttps://twitter.com/cocrystalpharma>span classeqicon-social-01-twitter>/span>/a>/li> li>a target_blank class hrefhttps://www.facebook.com/cocrystalpharma>span classeqicon-social-01-facebook>/span>/a>/li> li>a target_blank class hrefhttps://www.linkedin.com/company/cocrystal-pharma-inc->span classeqicon-social-01-linkedin>/span>/a>/li> /ul> /div> /div> div classmain-header> div classcontainer> div classrow> div classcol-md-3> h1 classlogo> a href/> img srchttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/header-logo.png data-at2xhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/header-logo@2x.png altCocrystal Pharma, Inc.> /a> /h1> /div> div classcol-md-9 nav-column> a classvisible-xs pull-right mobile-nav-trigger idshowRight> div classmeat>/div> div classmeat>/div> div classmeat>/div> /a> nav classcbp-spmenu cbp-spmenu-vertical cbp-spmenu-right main-nav idmobile-nav> ul classnav-justified> li classhas-children data-submenu-idsubmenu-about> a href/about>About/a> ul idsubmenu-about> li>a href/about/overview>Overview/a>/li> li>a href/about/management-team>Management Team/a>/li> li>a href/about/board-of-directors>Board of Directors/a>/li> li>a href/about/scientific-advisors>Scientific Advisors/a>/li> li>a href/about/careers>Careers/a>/li> /ul> /li> li class data-submenu-idsubmenu-technology> a href/technology>Technology/a> /li> li classhas-children data-submenu-idsubmenu-development-pipeline> a href/development-pipeline>Development Pipeline/a> ul idsubmenu-development-pipeline> li>a href/development-pipeline/overview>Overview/a>/li> li>a href/development-pipeline/influenza>Influenza/a>/li> li>a href/development-pipeline/norovirus>Norovirus/a>/li> li>a href/development-pipeline/coronavirus>Coronavirus/a>/li> li>a href/development-pipeline/respiratory-viruses>Respiratory Viruses/a>/li> li>a href/development-pipeline/hepatitis-c>Hepatitis C/a>/li> /ul> /li> li classhas-children data-submenu-idsubmenu-news> a href/news>News/Media/a> ul idsubmenu-news> li>a href/news/press-releases>Press Releases/a>/li> li>a href/news/presentations>Presentations/a>/li> li>a href/news/posters>Posters/a>/li> li>a href/news/multimedia-videos>Media/a>/li> /ul> /li> li classhas-children data-submenu-idsubmenu-investors> a href/investors>Investors/a> ul idsubmenu-investors> li>a href/investors/_>Overview/a>/li> li>a href/investors/analyst-coverage>Analyst Coverage/a>/li> li>a href/investors/news-events>News / Events/a>/li> li>a href/investors/ir-calendar>IR Calendar/a>/li> li>a href/investors/presentations>Presentations/a>/li> li>a href/investors/company-information>Company Information/a>/li> li>a href/investors/financial-information>Financial Information/a>/li> li>a href/investors/stock-data>Stock Data/a>/li> li>a href/investors/sec-filings>SEC Filings/a>/li> li>a href/investors/corporate-governance>Corporate Governance/a>/li> /ul> /li> li class data-submenu-idsubmenu-contact-us> a href/contact-us>Contact Us/a> /li> /ul> /nav> /div> /div> /div> /div>/header>div classnotice-banner > div classcontainer> h3 classmodule-title> /h3> p>We are a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. Our antivirals target the replication process and are designed to be safe, broad-spectrum, resistant and convenient to administer./p>p styletext-align: center;>We are quickly and efficiently advancing multiple programs with clinical development underway for influenza, norovirus and coronaviruses, while also discovering and developing antiviral compounds for other high-value indications./p> /div>/div> div classcycle-slideshow home-slides data-cycle-manual-fxscrollHorz data-cycle-pause-on-hovertrue data-cycle-slides> .slide data-cycle-swipetrue data-cycle-timeout0 data-cycle-logfalse data-cycle-pager#cycle-pager> div classslide home-hero background active data-bg-imagehttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/db/84/220/image.jpg> div classcontainer vertical-align> div classwrapper text dark> h2> Targeted Solutions for Viral Diseases /h2> p>Novel antiviral therapeutics for the treatment of serious and/or chronic viral diseases including influenza, COVID-19, hepatitis C and gastroenteritis caused by norovirus./p> a href/development-pipeline classbtn>View Product Pipeline/a> /div> /div> /div>!-- // slide 0 --> /div>div classhome-module background data-bg-color#fff> div classcontainer> div classhome-modules> div classrow js-same-height-row> div classcol-sm-4> div classbackground teaser-background data-bg-imagehttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/db/Teasers/223/image.jpg>/div> div classtext single-home-module gradient-bg-3 js-same-height bottom-btn dark> h3>About Us/h3> p>Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus./p> a href/about classbtn>Learn More/a> /div> /div>div classcol-sm-4> div classbackground teaser-background data-bg-imagehttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/db/Teasers/221/image.jpg>/div> div classtext single-home-module gradient-bg-1 js-same-height bottom-btn dark> h3>Technology/h3> p>We utilize unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs./p> a href/technology classbtn>Learn More/a> /div> /div>div classcol-sm-4> div classbackground teaser-background data-bg-imagehttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/db/Teasers/222/image.jpg>/div> div classtext single-home-module gradient-bg-2 js-same-height bottom-btn dark> h3>Development Programs/h3> p>Our development programs include a wide variety of serious and/or chronic viral diseases including influenza, COVID-19, hepatitis C and gastroenteritis caused by norovirus./p> a href/development-pipeline classbtn>Learn More/a> /div> /div> /div> /div> div classpipeline-wrapper> div classpipeline> table classpipeline-chart idpipeline> thead> tr> th classphase colspan2>Program/th> th>Discovery/th> th>Preclinical/th> th>Phase 1/th> th>Phase 2/th> th>Phase 3/th> /tr> /thead> tbody> tr class color-purple-three> td> span classdescription>Norovirus/span> /td> td> a href/development-pipeline/norovirus> Oral Pan-viral protease Inhibitor CDI-988 /a> /td> td classp-0 discovery candidate-phase> div classstatus complete> span classtext>Discovery Phase complete/span> /div> /td> td classp-1 preclinical candidate-phase> div classstatus complete> span classtext>Preclinical Phase complete/span> /div> /td> td classp-2 phase-1 candidate-phase> div classstatus in-progress stylewidth:80%;> span classtext>Phase 1 Phase in progressspan classarrow>/span>/span> div classphase-note phase-note-desktop>Phase 1 complete br>Phase 1b to begin in H1 2026/div> /div> /td> td classp-3 phase-2 candidate-phase> div classstatus not-started> span classtext>Phase 2 Phase not started/span> /div> /td> td classp-4 phase-3 candidate-phase> div classstatus not-started> span classtext>Phase 3 Phase not started/span> /div> /td> td classphase-note-mobile-cell> div classphase-note phase-note-mobile>Phase 1 complete br>Phase 1b to begin in H1 2026/div> /td> /tr> tr class color-purple-three> td> span classdescription>Coronavirus/span> /td> td> a href/development-pipeline/coronavirus> Oral Pan-viral protease Inhibitor CDI-988 /a> /td> td classp-0 discovery candidate-phase> div classstatus complete> span classtext>Discovery Phase complete/span> /div> /td> td classp-1 preclinical candidate-phase> div classstatus complete> span classtext>Preclinical Phase complete/span> /div> /td> td classp-2 phase-1 candidate-phase> div classstatus in-progress stylewidth:80%;> span classtext>Phase 1 Phase in progressspan classarrow>/span>/span> div classphase-note phase-note-desktop>Phase 1 complete/div> /div> /td> td classp-3 phase-2 candidate-phase> div classstatus not-started> span classtext>Phase 2 Phase not started/span> /div> /td> td classp-4 phase-3 candidate-phase> div classstatus not-started> span classtext>Phase 3 Phase not started/span> /div> /td> td classphase-note-mobile-cell> div classphase-note phase-note-mobile>Phase 1 complete/div> /td> /tr> tr class color-purple-three> td> span classdescription>Rhinovirus/span> /td> td> a href/development-pipeline/respiratory-viruses> Pan-viral protease inhibitor /a> /td> td classp-0 discovery candidate-phase> div classstatus complete> span classtext>Discovery Phase complete/span> /div> /td> td classp-1 preclinical candidate-phase> div classstatus in-progress stylewidth:50%;> span classtext>Preclinical Phase in progressspan classarrow>/span>/span> div classphase-note phase-note-desktop>Lead discovery ongoing/div> /div> /td> td classp-2 phase-1 candidate-phase> div classstatus not-started> span classtext>Phase 1 Phase not started/span> /div> /td> td classp-3 phase-2 candidate-phase> div classstatus not-started> span classtext>Phase 2 Phase not started/span> /div> /td> td classp-4 phase-3 candidate-phase> div classstatus not-started> span classtext>Phase 3 Phase not started/span> /div> /td> td classphase-note-mobile-cell> div classphase-note phase-note-mobile>Lead discovery ongoing/div> /td> /tr> tr class color-blue-one> td> span classdescription>Influenza A/span> /td> td> Oral PB2 inhibitor CC-42344 /td> td classp-0 discovery candidate-phase> div classstatus complete> span classtext>Discovery Phase complete/span> /div> /td> td classp-1 preclinical candidate-phase> div classstatus complete> span classtext>Preclinical Phase complete/span> /div> /td> td classp-2 phase-1 candidate-phase> div classstatus complete> span classtext>Phase 1 Phase complete/span> /div> /td> td classp-3 phase-2 candidate-phase> div classstatus in-progress stylewidth:50%;> span classtext>Phase 2 Phase in progressspan classarrow>/span>/span> div classphase-note phase-note-desktop>Phase 2a challenge study complete/div> /div> /td> td classp-4 phase-3 candidate-phase> div classstatus not-started> span classtext>Phase 3 Phase not started/span> /div> /td> td classphase-note-mobile-cell> div classphase-note phase-note-mobile>Phase 2a challenge study complete/div> /td> /tr> tr class color-blue-one> td> span classdescription>Influenza A/span> /td> td> Inhaled PB2 inhibitor CC-42344 /td> td classp-0 discovery candidate-phase> div classstatus complete> span classtext>Discovery Phase complete/span> /div> /td> td classp-1 preclinical candidate-phase> div classstatus in-progress stylewidth:100%;> span classtext>Preclinical Phase completespan classarrow>/span>/span> div classphase-note phase-note-desktop>GLP tax study complete/div> /div> /td> td classp-2 phase-1 candidate-phase> div classstatus not-started> span classtext>Phase 1 Phase complete/span> /div> /td> td classp-3 phase-2 candidate-phase> div classstatus not-started> span classtext>Phase 2 Phase complete/span> /div> /td> td classp-4 phase-3 candidate-phase> div classstatus not-started> span classtext>Phase 3 Phase complete/span> /div> /td> td classphase-note-mobile-cell> div classphase-note phase-note-mobile>GLP tax study complete/div> /td> /tr> tr class color-blue-one> td> span classdescription>Influenza A & B/span> /td> td> Oral replication inhibitor /td> td classp-0 discovery candidate-phase> div classstatus complete> span classtext>Discovery Phase complete/span> /div> /td> td classp-1 preclinical candidate-phase> div classstatus in-progress stylewidth:60%;> span classtext>Preclinical Phase in progressspan classarrow>/span>/span> div classphase-note phase-note-desktop>Lead discovery ongoing NIH SBIR Funded/div> /div> /td> td classp-2 phase-1 candidate-phase> div classstatus not-started> span classtext>Phase 1 Phase not started/span> /div> /td> td classp-3 phase-2 candidate-phase> div classstatus not-started> span classtext>Phase 2 Phase not started/span> /div> /td> td classp-4 phase-3 candidate-phase> div classstatus not-started> span classtext>Phase 3 Phase not started/span> /div> /td> td classphase-note-mobile-cell> div classphase-note phase-note-mobile>Lead discovery ongoing NIH SBIR Funded/div> /td> /tr> /tbody> /table> /div> /div> /div>/div>div classir-presentation-bar> div classcontainer center> h2>Investor Presentation/h2> p>View our latest Corporate Presentation/p> a target_blank hrefhttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/db/102/535/pdf/COCP+Investor+Presentation+-+112625+final.pdf classbtn>View Presentation/a> /div>/div> div classhome-ir-module> div classcontainer> div classrow js-same-height-row> div classcol-sm-6 js-same-height home-news-col> div classhome-latest-news> h2 classmodule-title>Latest News/h2> article> span classdate> December 18, 2025 • /span> a href/news/press-releases/detail/222/cocrystal-pharma-receives-irb-approval-from-emory>Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus/a> /article> article> span classdate> December 01, 2025 • /span> a href/news/press-releases/detail/221/cocrystal-pharma-to-present-at-the-noble-capital-markets>Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference/a> /article> /div> /div> div classcol-sm-6 single-home-module module-info-home quote-box js-same-height data-symbolCOCP> h2 classmodule-title> Stock Data span classmeta> span classtime> /span> a href/investors>View Investor Relations/a> /span> /h2> div classrow> div classcol-md-3 col-sm-6 stock-section> span classvalue-title>Nasdaq:/span> span classvalue pull-left>COCP/span> span classprice>span classvalue cost pull-right>img srchttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/ajax-loader.gif altLoading...>/span>/span> /div> div classcol-md-3 col-sm-6 change stock-section> span classvalue-title>Change/span> span> span classeqicon-change-04>/span> span classvalue>img srchttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/ajax-loader.gif altLoading...>/span> /span> /div> div classcol-md-3 col-sm-6 volume stock-section> span classvalue-title>Volume/span> span classvalue>img srchttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/ajax-loader.gif altLoading...>/span> /div> div classcol-md-3 col-sm-6 market-cap stock-section> span classvalue-title>Market Cap/span> span classvalue>img srchttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/ajax-loader.gif altLoading...>/span>/span> /div> /div> /div> /div> /div> /div> /div> div classpre-footer background data-bg-imagehttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/images/email-alerts-bg.jpg> div classcontainer center> h2>Sign Up for Email Alerts/h2> p>Be the first to receive breaking news/p> a hrefhttps://ir.cocrystalpharma.com/email-alerts classbtn>Sign Up/a> /div> /div>footer class> div classcontainer> div classcopyright pull-left> © 2026 Cocrystal Pharma, Inc. div classfooter-links> a href/site-info/privacy-policy>Privacy Policy/a> a href/site-info/disclaimer>Disclaimer/a> a href/site-info/sitemap>Site Map/a> /div> /div> div classpull-right footer-social> ul> li>a target_blank class hrefhttps://twitter.com/cocrystalpharma>span classeqicon-social-01-twitter>/span>/a>/li> li>a target_blank class hrefhttps://www.facebook.com/cocrystalpharma>span classeqicon-social-01-facebook>/span>/a>/li> li>a target_blank class hrefhttps://www.linkedin.com/company/cocrystal-pharma-inc->span classeqicon-social-01-linkedin>/span>/a>/li> /ul> /div> /div>/footer>script idcompanyVars typeapplication/json>{ hCaptchaSiteKey: 778a5748-d323-4b73-a06c-9625642de8bc}/script>script> var asset_url https://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma; var website_base_url https://www.cocrystalpharma.com; var ir_base_url https://ir.cocrystalpharma.com;/script>script srchttps://content.equisolve.net/_8c3dfc53c48ac01ff48f5a7c00f6a51a/cocrystalpharma/files/js/_js/all.js>/script>script typetext/javascript> var jqxhr $.get( https://www.cocrystalpharma.com/api/v1/quote, function(data) { populateQuoteBox(data); });/script> /body>/html>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]